Total Payments
$50,410
2024 Payments
$3,905
Companies
13
Transactions
56
Medicare Patients
796
Medicare Billing
$100,254
Payment Breakdown by Category
Consulting$43,825 (86.9%)
Other$3,130 (6.2%)
Travel$2,045 (4.1%)
Food & Beverage$1,398 (2.8%)
Education$11.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $43,825 | 19 | 86.9% |
| Honoraria | $2,638 | 2 | 5.2% |
| Travel and Lodging | $2,045 | 12 | 4.1% |
| Food and Beverage | $1,398 | 19 | 2.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $272.25 | 2 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $220.59 | 1 | 0.4% |
| Education | $11.50 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $16,291 | 19 | $0 (2024) |
| Kite Pharma, Inc. | $7,900 | 10 | $0 (2023) |
| Genentech USA, Inc. | $7,299 | 4 | $0 (2024) |
| Genentech, Inc. | $6,000 | 2 | $0 (2023) |
| Incyte Corporation | $5,228 | 2 | $0 (2021) |
| Merck Sharp & Dohme LLC | $2,222 | 4 | $0 (2024) |
| BeiGene USA, Inc. | $2,137 | 3 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $1,938 | 1 | $0 (2020) |
| Epizyme, Inc., | $711.50 | 2 | $0 (2022) |
| ADC Therapeutics America, Inc. | $421.16 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,905 | 7 | Genentech USA, Inc. ($2,660) |
| 2023 | $14,938 | 20 | Kite Pharma, Inc. ($6,200) |
| 2022 | $6,113 | 7 | AstraZeneca Pharmaceuticals LP ($2,961) |
| 2021 | $6,169 | 4 | Incyte Corporation ($2,153) |
| 2020 | $11,165 | 5 | AstraZeneca Pharmaceuticals LP ($4,453) |
| 2019 | $79.10 | 1 | Genentech USA, Inc. ($79.10) |
| 2018 | $7,929 | 11 | AstraZeneca Pharmaceuticals LP ($6,429) |
| 2017 | $112.01 | 1 | Merck Sharp & Dohme Corporation ($112.01) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 2 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/08/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $85.32 | General |
| Category: CELLT | ||||||
| 01/18/2023 | Genentech, Inc. | Polivy (Biological) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: BioOncology | ||||||
| 12/10/2022 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $99.39 | General |
| 12/10/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $73.40 | General |
| 12/01/2022 | Genentech USA, Inc. | POLIVY (Biological) | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: BioOncology | ||||||
| 07/14/2022 | Epizyme, Inc., | — | Honoraria | Cash or cash equivalent | $700.00 | General |
| 03/01/2022 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $220.59 | General |
| 02/09/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 02/09/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 12/08/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 10/28/2021 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,152.50 | General |
| 02/19/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 01/07/2021 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 12/11/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $3,075.00 | General |
| 11/16/2020 | Kite Pharma, Inc. | Tecartus (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: CELLT | ||||||
| 11/06/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 08/12/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Honoraria | Cash or cash equivalent | $1,937.50 | General |
| Category: Oncology | ||||||
| 02/26/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 06/20/2019 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $79.10 | General |
| 10/16/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $5,350.00 | General |
| Category: Oncology | ||||||
| 06/15/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $355.39 | General |
| Category: Oncology | ||||||
| 06/15/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $271.36 | General |
| Category: Oncology | ||||||
| 06/15/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $221.89 | General |
| Category: Oncology | ||||||
| 06/15/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $108.64 | General |
| Category: Oncology | ||||||
| 06/15/2018 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $44.47 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 230 | 342 | $97,428 | $28,674 |
| 2022 | 3 | 163 | 231 | $52,244 | $18,404 |
| 2021 | 6 | 200 | 345 | $83,608 | $29,761 |
| 2020 | 6 | 203 | 339 | $94,894 | $23,415 |
Total Patients
796
Total Services
1,257
Medicare Billing
$100,254
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 69 | $25,813 | $8,037 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 106 | $27,249 | $7,381 | 27.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 45 | $14,895 | $4,582 | 30.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 50 | $11,052 | $3,386 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $7,441 | $2,093 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 35 | $6,045 | $1,657 | 27.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 22 | 22 | $4,934 | $1,536 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 85 | 131 | $28,625 | $9,808 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 55 | $16,985 | $6,310 | 37.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 45 | $6,634 | $2,286 | 34.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 87 | $26,309 | $10,506 | 39.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 83 | 117 | $25,050 | $9,035 | 36.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 67 | $18,975 | $5,945 | 31.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 34 | $6,699 | $2,099 | 31.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 22 | 23 | $3,202 | $1,111 | 34.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 16 | 17 | $3,373 | $1,065 | 31.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 90 | 133 | $36,646 | $7,960 | 21.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 68 | $18,058 | $6,218 | 34.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 55 | $20,314 | $4,449 | 21.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 50 | $8,995 | $1,791 | 19.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 13 | 13 | $7,307 | $1,736 | 23.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 20 | $3,575 | $1,261 | 35.3% |
About Dr. Stephen Smith, M.D
Dr. Stephen Smith, M.D is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1497925051.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Smith, M.D has received a total of $50,410 in payments from pharmaceutical and medical device companies, with $3,905 received in 2024. These payments were reported across 56 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($43,825).
As a Medicare-enrolled provider, Smith has provided services to 796 Medicare beneficiaries, totaling 1,257 services with total Medicare billing of $100,254. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Seattle, WA
- Active Since 03/10/2008
- Last Updated 10/10/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1497925051
Products in Payments
- CALQUENCE (Drug) $15,870
- Yescarta (Drug) $6,200
- Polivy (Biological) $3,000
- Venclexta (Biological) $2,660
- Columvi (Biological) $2,280
- POLIVY (Biological) $2,280
- BRUKINSA (Drug) $2,137
- XPOVIO (Drug) $1,938
- Tecartus (Drug) $1,700
- TAZVERIK (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Seattle
Mr. John Pesando, Md, MD
Hematology & Oncology — Payments: $12.8M
Hematology & Oncology $12.8M
John Pagel, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Langdon Miller, Md, MD
Hematology & Oncology — Payments: $674,815
Hematology & Oncology $674,815
Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD
Hematology & Oncology — Payments: $534,649
Hematology & Oncology $534,649
Barbara Konkle, Md, MD
Hematology & Oncology — Payments: $331,390
Hematology & Oncology $331,390
Dr. Jill Johnsen, Md, MD
Hematology & Oncology — Payments: $291,732
Hematology & Oncology $291,732